Skip to main content

Table 3 Adverse events during treatment

From: Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

 

Chemo-naïve (%)

Post-chemo (%)

 

Grade 1

Grade 2

Grade 3

Grade 4

Grade 1

Grade 2

Grade 3

Grade 4

Peripheral edema

6 (10.3)

0

3 (5.2)

0

2 (3.8)

1 (1.9)

0

0

Elevation of liver enzymes

7 (12.1)

0

0

0

3 (5.8)

0

1 (1.9)

0

Hypokalemia

15 (25.9)

1 (1.7)

2 (3.4)

0

9 (17.3)

2 (3.8)

2 (3.8)

0

Hypertension

9 (15.5)

7 (12.1)

4 (6.9)

0

17 (32.7)

3 (5.8)

3 (5.8)

0

Fatigue

1 (1.7)

0

0

0

1 (1.9)

0

0

0

Arthralgia

0

0

0

0

1 (1.9)

0

0

0

Diarrhoea

0

0

0

0

1 (1.9)

0

0

0

Dyspepsia

1 (1.7)

0

0

0

0

0

0

0